STOCK TITAN

Planned sale: Core Scientific (CORZ) officer disposes 10,000 shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on April 13, 2026, in two transactions pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted average prices within ranges of $17.94–$18.90 and $18.97–$19.04 per share. Following these sales, Duchene directly holds 2,027,089 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider DUCHENE TODD M
Role See remarks
Sold 10,000 shs ($186K)
Type Security Shares Price Value
Sale Common Stock 9,600 $18.6094 $179K
Sale Common Stock 400 $18.9925 $8K
Holdings After Transaction: Common Stock — 2,027,489 shares (Direct)
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.97 to $19.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Total shares sold 10,000 shares Open-market sales on April 13, 2026
First block sold 9,600 shares at $18.6094 Weighted average price; trades ranged $17.94–$18.90
Second block sold 400 shares at $18.9925 Weighted average price; trades ranged $18.97–$19.04
Post-transaction holdings 2,027,089 shares Direct ownership after April 13, 2026 sales
Trading plan adoption date December 5, 2025 Rule 10b5-1 plan governing reported sales
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DUCHENE TODD M

(Last)(First)(Middle)
C/O CORE SCIENTIFIC, INC.
838 WALKER ROAD, SUITE 21-2105

(Street)
DOVER DELAWARE 19904

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/13/2026S(1)9,600D$18.6094(2)2,027,489D
Common Stock04/13/2026S(1)400D$18.9925(3)2,027,089D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.97 to $19.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Remarks:
Chief Legal and Administrative Officer
/s/ Todd DuChene04/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CORZ officer Todd M. Duchene report?

Todd M. Duchene reported selling 10,000 shares of Core Scientific (CORZ) Common Stock in open-market transactions. The sales occurred in two blocks of 9,600 and 400 shares, both executed on April 13, 2026, as reflected in the Form 4 filing.

At what prices were the CORZ shares sold in this Form 4 filing?

The reported prices are weighted averages of multiple trades. One 9,600-share sale averaged $18.6094 within a $17.94–$18.90 range. The 400-share sale averaged $18.9925 within a $18.97–$19.04 range, as disclosed in the filing’s footnotes.

How many Core Scientific (CORZ) shares does Todd M. Duchene hold after the sale?

After the reported open-market sales, Todd M. Duchene directly holds 2,027,089 shares of Core Scientific Common Stock. This post-transaction balance shown in the Form 4 indicates he retains a substantial equity position following the 10,000-share disposition.

Was the CORZ insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted by Todd M. Duchene on December 5, 2025. Such plans pre-schedule trades, helping separate routine portfolio moves from discretionary timing decisions.

What is the total number of CORZ shares sold in this Form 4?

The Form 4 shows a total sale of 10,000 Core Scientific Common Stock shares. This comprises 9,600 shares sold at a weighted average price of $18.6094 and 400 shares sold at a weighted average price of $18.9925, both on April 13, 2026.